Articles related to ANEMIA

The use of reticulocyte hemoglobin content (CHr) presents a significant advancement in diagnosing iron-deficiency anemia. CHr’s potential in early detection, differentiation of hematologic conditions, and real-time assessment could pave the way for more precise and timely patient care.

Recent findings suggest a link between daily low-dose aspirin intake and elevated anemia incidence and ferritin decline in older adults, highlighting the necessity for periodic monitoring of hemoglobin in these patients.

In this “Letters to Blood,” the author demonstrated that luspatercept provided prolonged periods of transfusion independence (TI), significantly decreased the transfusion burden among HTB and LTB patients, and generally had an acceptable and predictable safety profile, all of which helped to maintain or enhance patient quality of life. Compared to the results from the primary analysis, these data further demonstrate the clinical benefits of luspatercept in patients with LR-MDS-RS.

Blue sclera has an 87% to 89% sensitivity and a 64% to 94% specificity for iron deficiency anemia and iron deficiency in adults (ie, anemia need not always be present). Blue sclera has been reported, albeit infrequently, in other conditions such as rheumatoid arthritis, myasthenia gravis, and long-term steroid therapy.

Srdan Verstovsek, MD, PhD of MD Anderson Cancer Center, is interviewed for answers to the questions of when to start treatment in a patient with myelofibrosis, an update on current treatment options, considerations for selecting treatment, dose optimization, sequencing of therapy, and more.

A newly developed prolyl hydroxylase inhibitor (agents that increase endogenous erythropoietin production) holds the promise of improving outcomes for patients with anemia of chronic kidney disease. Randomized controlled trials have found these drugs to be at least as effective as erythropoiesis-stimulating agents.